Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01831466 · ClinicalTrials.gov registry record · Phase 2
Tofacitinib Ointment For Chronic Plaque Psoriasis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 476
- Enrollment target
NCT01831466: Completed Phase 2 study, sponsored by Pfizer.
NCT01831466 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 476 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (258% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01831466, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 476 participants
- Enrollment target
Study Summary
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be compared to the safety and effectiveness of placebo ointment (vehicle) used for 12 weeks.
Primary Outcome
Clinical signs of plaque psoriasis (erythema \[E\], induration \[I\], and scaling \[S\]) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher scor
Interventions
- DRUG tofacitinib ointment 20 mg/g
- DRUG tofacitinib ointment 10 mg/g
- DRUG placebo ointment (vehicle)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 476 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
What the finished NCT01831466 record still lists
NCT01831466 is an interventional study that assigns participants to a tested intervention. The registered 476 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (258% higher).
The record links to 0 conditions, and to 3 interventions - of which tofacitinib ointment 20 mg/g is the first listed.
NCT01831466 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01831466 about?
NCT01831466 is a clinical study titled "Tofacitinib Ointment For Chronic Plaque Psoriasis". The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be...
What is the current status of trial NCT01831466?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 476 participants. The study started on 2013-05. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01831466?
The interventions under investigation include: tofacitinib ointment 20 mg/g (DRUG), tofacitinib ointment 10 mg/g (DRUG), placebo ointment (vehicle) (DRUG).
Who is sponsoring clinical trial NCT01831466?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01831466's enrollment target sits among peer trials
476 77th of 2000 higher than 1,924 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06754046 · 476 participants · NA
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
- NCT06997497 · 477 participants · Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia